Overactive Bladder Treatment Market - By Condition Type (Neurogenic, Idiopathic], Treatment Type (Drug Therapy [Anticholinergic, Beta-3 Adrenoceptor Agonist], Botox Treatment, Neuromodulation), Age Group (31-50, 51-60) – Global Forecast (2024 – 2032)

Overactive Bladder Treatment Market Size

Overactive Bladder Treatment Market size was valued at USD 3.5 billion in 2023 and is estimated to grow at 4.3% CAGR from 2024 to 2032. The market has experienced significant growth due to the increasing prevalence of various conditions that cause overactive bladder such as urinary tract infections, diabetes, bladder cancer, and neurological disorders including Parkinson's disease and stroke.
 

For instance, according to an article published by the StatPearls Journal in November 2022, approximately 40% of women in the U.S. are estimated to develop a urinary tract infection at least once in their lifetime. Therefore, the high incidence of urinary tract infections is expected to drive the demand for overactive bladder treatments during the forecast period. Moreover, initiatives by healthcare organizations and governments to improve access to healthcare services and develop novel treatments also play a significant role in driving market demand.
 

Overactive bladder treatment comprehends a range of therapies aimed at managing symptoms associated with the condition which include frequent urination, sudden urges to urinate, and urinary incontinence. These treatments typically focus on improving bladder function and reducing symptoms. The treatment approaches include medications such as anticholinergics and beta-3 adrenoceptor agonists, prescribed to regulate bladder muscle spasms and relax the detrusor muscles. In addition, advanced treatment options include botulinum toxin injections and neuromodulation among other therapies involved to treat the symptoms and relax the bladder.
 

Overactive Bladder Treatment Market Trends

Advancements in the treatment of overactive bladder coupled with a growing demand for minimally invasive options are propelling market demand. Innovations such as neuromodulation, an electrical stimulator that uses electrical impulses to regulate bladder activity, and help relax bladder muscles, offer effective alternatives to traditional treatments. This therapy is designed to offer substantial symptom relief with fewer side effects and shorter recovery times, has captured significant attention, thereby fueling market demand.
 

• For instance, in February 2024, Avation Medical, an innovative neuromodulation and digital health company introduced its Vivally System. Vivally is the first and only non-invasive, FDA-cleared, wearable neuromodulation system for home use that delivers closed-loop, autonomously adjusted electrical stimulation to treat patients with urge urinary incontinence and urinary urgency caused by overactive bladder syndrome. This launch marked a significant advancement in the non-invasive treatment options available for overactive bladder patients.
   

Therefore, ongoing research for the development of combined therapies and innovative approaches to enhance treatment effectiveness are few factors fostering the expansion of the market.
 

Overactive Bladder Treatment Market Analysis

Based on the condition type, the market is categorized into neurogenic bladder overactivity and idiopathic bladder overactivity. The idiopathic bladder overactivity segment is set to lead the market, generating the highest revenue of USD 2.8 billion, with projections to reach USD 4 billion by 2032.
 

• Idiopathic or non-neurogenic overactive bladder occurs when the nerve pathways in the bladder malfunction without an identifiable neurological cause. Therefore, addressing the global concern for bladder malfunction has led governments to focus on proactive approaches, ensuring more consistent and effective management of overactive bladder.
   
• For instance, the American Urological Association amended guidelines in September 2019 to provide a clinical framework for diagnosing and treating non-neurogenic overactive bladder. Thus, increasing government support for standardizing care practices to improve treatment outcomes is driving market growth.

Based on treatment type, the overactive bladder treatment market is classified into drug therapy, botox treatment, neuromodulation, and other treatment types. The drug therapy segment holds the largest market share of 48.9% in 2023 and is expected to maintain dominance throughout the analysis period.

• Drug therapies are widely prescribed due to their efficacy in managing overactive bladder symptoms. Mirabegron, a beta-3 adrenoceptor agonist available as an extended-release oral tablet that effectively manages symptoms such as urge urinary incontinence, urgency, and frequent urination is expected to spur the segmental growth.
   
• Additionally, regulatory support, exemplified by the FDA's approval for treating neurogenic detrusor overactivity in children, further bolsters segment growth.
  
   

Based on age group, the market is segmented into 18-30, 31-50, 51-60, and 60 above. The 51-60 age group segment is expected to exhibit CAGR of 4.2% during the analysis period.
 

• The 51-60 age group dominated the overactive bladder treatment industry driven by the higher prevalence of overactive bladder symptoms in this demographic.
   
• As people age, the incidence of conditions such as urgency, urinary incontinence, and frequent urination increases, leading to a greater demand for effective treatments. Also, this age group is more proactive in seeking medical assistance, contributing to the higher market share.
   
• Thus, the availability of advanced therapies and increased awareness pertaining to overactive bladder among individuals in this age range further support the market dominance.

The U.S. dominated the North American overactive bladder treatment market accounting for USD 1.4 billion in 2023 and is anticipated to show significant growth over the analysis period.
 

• The market growth is due to factors such as the rising prevalence of overactive bladder, presence of market key players and strong research and development background.
   
• For instance, Viatris Inc. is currently developing Onabotulinumtoxin A (botox) as a potential treatment for overactive bladder and cervical dystonia. The company aims to launch this product by 2026, subject to regulatory approvals. The introduction of this new therapy is expected to contribute to the growth of the OAB treatment.
   
• Thus, ongoing research activities and the availability of advanced treatment options, favorable reimbursement policies, and extensive healthcare infrastructure contribute to the U.S. market growth.
   

Germany exhibited a high growth potential in the European market.
 

• Germany is a key player in the overactive bladder treatment industry in Europe, with a strong healthcare infrastructure and a focus on innovative therapies.
   
• The country's market for overactive bladder treatment benefits from factors such as advanced medical research, a high prevalence of overactive bladder cases, and the presence of leading pharmaceutical companies.
   
• For instance, according to the German Continence Society, over 10 million people in Germany are affected by urinary incontinence, a common symptom of an overactive bladder. The substantial increase in cases has driven the demand for effective treatment options, thereby fueling the expansion of the market in Germany.
   
• In addition, the country's robust pharmaceutical industry and emphasis on research and development drive innovation and market expansion in overactive bladder treatment.
   

Asia Pacific overactive bladder treatment market is poised for rapid growth with a CAGR of 4.7% during the forecast period.
 

• The Asia Pacific region presents significant growth opportunities in the market owing to factors such as rising healthcare infrastructure development and increasing awareness about urinary disorders.
   
• The increasing prevalence of overactive bladder across the region is anticipated to bolster the demand for overactive bladder medications and treatments, thereby supporting the regional market.
   
• Additionally, the proliferation of product launches and the presence of numerous industry participants contribute to the regional market's growth. For instance, in November 2021, Taiho Pharmaceutical Co., Ltd. launched BUP-4 LADY, an over-the-counter (OTC) drugs for urinary urgency in Japan. This product was introduced in non-dispensing pharmacies, drug stores, and dispensing pharmacies across Japan. Hence, the increasing number of product launches and expanding research endeavors are expected to propel significant growth in the region in the coming years.
   

Overactive Bladder Treatment Market Share

The overactive bladder treatment industry is highly competitive, including prominent pharmaceutical companies and emerging biotech companies. Key players in the market are offering effective drugs such as anticholinergics and beta-3 adrenergic agonists. Innovations in minimally invasive treatments, such as botox injections by Allergan and neuromodulation therapies by Medtronic, have further intensified competition.
 

Overactive Bladder Treatment Market Companies

Few of the prominent players operating in the industry include:

• AbbVie Inc.
• Astellas Pharma Inc.
• Axonics, Inc.
• BlueWind Medical
• Cipla Ltd.
• Endo International plc
• Laborie
• Lupin Ltd.
• Medtronic plc
• Merck & Co.
• Pfizer, Inc
• Sumitomo Pharma America, Inc (Urovant Sciences.)
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Zydus Lifesciences Ltd.
   

Overactive Bladder Treatment Industry News:

• In April 2024, Zydus Lifesciences Ltd. introduced Mirabegron extended-release tablets, 25 mg, in the U.S. market. Mirabegron is used to treat overactive bladder, addressing symptoms such as urge urinary incontinence, urgency, and urinary frequency. This prominent launch is expected to enhance the company's portfolio for urinary disorders and solidify its presence in the U.S. market.
   
• In May 2023, MSN Labs introduced Fesobig, the world's inaugural bioequivalent generic iteration of Fesoterodine Fumarate. Fesobig is recommended as the safest and innovative primary pharmacotherapy selection for addressing overactive bladder and urinary incontinence. This launch enabled company to add value to its existing portfolio.
   

The overactive bladder treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Condition Type

• Neurogenic bladder overactivity
• Idiopathic bladder overactivity

Market, By Treatment Type

• Drugs therapy
  • Anticholinergics
  • Beta-3 adrenoceptor agonists 
• Botox treatment
• Neuromodulation
• Other treatment types

Market, By Age Group

• 18-30
• 31-50
• 51-60
• 60 above

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa